Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.010
+0.230 (6.08%)
At close: Aug 13, 2025, 4:00 PM
4.230
+0.220 (5.49%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
Aquestive Therapeutics Employees
Aquestive Therapeutics had 142 employees as of December 31, 2024. The number of employees increased by 7 or 5.19% compared to the previous year.
Employees
142
Change (1Y)
7
Growth (1Y)
5.19%
Revenue / Employee
$310,789
Profits / Employee
-$458,042
Market Cap
399.89M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AQST News
- 2 hours ago - Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 3 hours ago - Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film - GlobeNewsWire
- 1 day ago - Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film - GlobeNewsWire
- 5 weeks ago - Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval - Seeking Alpha